Mahmut Gümüş

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Giannis Mountzios, Longhua Sun, Byoung Chul Cho et al. · New England Journal of Medicine · 2025 · 180 citations · Full text

Medicine, Oncology, Pharmacology +14

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Katriina Peltola et al. · New England Journal of Medicine · 2024 · 142 citations

Medicine, Oncology, Pharmacology +17

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et al. · The Lancet Oncology · 2023 · 96 citations

Medicine, Oncology, Pharmacology +15

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16